November 16, 2026 at 01:14 PM UTC
Akebia Therapeutics, Inc. reports material agreement in SEC 8-K
Akebia Therapeutics, Inc. filed an 8-K covering a material definitive agreement, termination of a material definitive agreement, a direct financial obligation, and an unregistered sale of equity securities. Nelo verified the filing topics against the primary SEC document. This is a company disclosure filed with the SEC, not an SEC enforcement action.
Official source: U.S. Securities and Exchange Commission
Official source published: November 16, 2026 at 01:12 PM UTC
Open official source